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Sum of its Parts
Combining CT Angiography and Highly Sensitive Troponin in
the Diagnostic Work-Up of Patients With Acute Chest Pain*Fabian Bamberg, MD, MPHF irst coined by the philosopher Aristotle, thephrase “the whole is greater than the sum ofits parts” aptly deﬁnes the modern concept
of synergy in which the combination of different en-
tities results in substantially improved outcomes
compared to single-entitybased approaches. By
combining 2 diagnostic pathways of imaging and
serum biomarkers, the study by Ferencik et al. (1) in
this issue of iJACC tantalizingly expands on diag-
nostic synergistic workﬂows and adds to the existing
scientiﬁc literature (1).SEE PAGE 1272In the ﬁeld of cardiovascular computed tomogra-
phy (CT) imaging, such thinking has not been pursued
extensively. Early research efforts focused on the
improvement of the diagnostic accuracy and reduc-
tion of site-effects over the different scanner gen-
erations (2). It just happened recently, 10 years after
the introduction of 64-slice CT, that the clinical
effectiveness of applying cardiac computed tomog-
raphy angiography (CTA) to different clinical settings
has become an important research subject.
The ROMICAT II (Rule Out Myocardial Infarction/
Ischemia using Computer Assisted Tomography) trial
was a randomized diagnostic trial to determine the
value of cardiac CTA in the workup of patients with
acute chest pain. This trial is a superb example of the*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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Bayer Healthcare (Berlin, Germany).efforts used to determine the clinical effectiveness of
a matured imaging technology for broader clinical
applicability (3). Consistent with a second random-
ized diagnostic trial (ACRIN [American College of
Radiology Imaging Network PA4005]), ROMICAT II
demonstrated that a CTA-based workup strategy al-
lows early discharge (4), particularly in women (5),
without altering safety (6).
However, the clinical decision making is less
obvious on an individual patient basis. The imaging
ﬁndings used for clinical decisions are usually cate-
gorized as no coronary artery disease (CAD), the
presence of nonobstructive CAD, or the presence of a
signiﬁcant coronary stenosis (deﬁned as a stenosis
exceeding 50% luminal narrowing). Unfortunately,
the proportion of subjects at intermediate risk, usu-
ally the group with nonobstructive CAD, remains high
(w40% to 50%) and is characterized by a 4% to 5%
acute coronary syndrome (ACS) rate. Thus, these
subjects require subsequent work-up and testing.
There are several approaches to using additional CT
information that enable further stratiﬁcation of the
intermediate risk category. These approaches include
the assessment of left ventricular function (7), myo-
cardial perfusion (8), advanced plaque analysis (9), or
fractional ﬂow reserve simulations based on CT data
(10). However, despite their scientiﬁc value, these ap-
proaches have not been adopted in clinical practice due
to their speciﬁc acquisition protocols, insensitivity, or
labor-intensive nature. Also, there are promising,
non—imaging based strategies, such as high-sensi-
tivity (hs) troponin (Tn) assays emerging (11).
In this issue of iJACC, Ferencik et al. (1) present an
elegant analysis of the ROMICAT II trial to determine
the effect of combining traditional CTA ﬁndings with
advanced plaque analysis and results from hsTn I
tests at the time of presentation to the emergency
department. This study provides unique insights into
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pathways.
It is an intriguing ﬁnding that both diagnostic stra-
tegies share a common challenge, as they leave many
subjects in the intermediate risk category (43.8% and
86.9% for CT and hsTn, respectively). Thus, a new
understanding of how to interpret very low levels of
hsTn produced by higher sensitivity assays may be
required. Similarly, the highly sensitive CTA ﬁnding of
atherosclerotic plaque mandates improved apprecia-
tion for the role of plaque in the disease process. Both
characteristics are evident in Table 5 of the paper,
which demonstrates that the speciﬁcity and the asso-
ciated positive predictive value are relatively low
(48.2% and 20.7%, respectively).
Although the effect of a combined approach in
excluding the presence of ACS is exquisitely shown in
the analysis, the effect size is moderate (see Figure 5
in Ferencik et al. [1]). According to the initial hsTn
results, only 13% of subjects could avoid a CT exam-
ination, and approximately 5.6% were reclassiﬁed for
immediate discharge (due to values below the level of
detection). Additionally, 7.5% of patients were iden-
tiﬁed for high-risk management (value >99th
percentile). Following the advanced CT analysis,
there was a relatively small fraction of subjects
further reclassiﬁed for immediate discharge (absence
of high-risk plaque in 27 of 139, 19.4%) because no
plaque was detected in the majority of patients (60 of
139). This is also evident from Table 5 (1) showing that
the positive predictive value can only be increased to
29.7%. Table 5 (1) shows the positive predictive value
can only be increased to 29.7%. The largest impact of
excluding ACS in this population is attributed to the
absence of plaque on CT (42.5%). Therefore, the effect
of the hsTn measurement remains relatively small.
Thus, major advancements are needed to improve
the discriminatory power of the initial hsTn mea-
surement, a ﬁeld of research that is currently
emerging impressively. The challenges to hsTn assays
include a lack of industry standards that result in
varying assay characteristics and hamper compari-
sons between hospitals and medical systems (see
Online Table 1 in Ferencik et al. [1]). The potential of
biological variability also makes interpreting hsTn
elevations difﬁcult, and new thresholds must be
deﬁned for clinical use (12).
The current analysis does not include other clinical
markers of risk that are also available for clinicaldecision-making. In pooling data from the ADAPT (A
2-hr Accelerated Diagnostic Protocol to Assess pa-
tients with chest Pain symptoms using contemporary
Troponins as the only biomarker) and APACE (Ad-
vantageous Predictors of acute Coronary Syndromes
Evaluation) trials, electrocardiogram, Thrombolysis
In Myocardial Infarction (TIMI) risk score, and serial
hsTn data permitted the safe discharge of up to a
quarter of patients (13). Thus, it can be assumed that
the combination of CTA results with hsTn and other
markers of risk will eventually lead to multi-
parametric diagnostic pathways and improved triage
in this challenging target population.
From an imaging perspective, the rapid availability
of CTA with feasible and automated workﬂows will
be essential to establishing imaging information in
these fast laboratory-driven pathways, presumably
with reporting times of approximately 1 h. A detailed
analysis requires substantial expertise and a com-
prehensive and time-consuming assessment of the
CTA datasets, which may not be feasible in a busy
emergency department environment on a broader
basis. Also, even in the specialized setting of a core
lab, the interobserver agreement for high-risk plaque
detection is inferior to that of traditional CTA ﬁndings
such as plaque and stenosis (kappa 0.69 vs. 0.77 and
0.80, respectively) (9). To overcome the restraint of
“unlimited time for image interpretation” available in
a research core lab, either advanced post-processing
tools or straightforward image criteria must be es-
tablished and veriﬁed in real-world scenarios.
In conclusion, the role of serum biomarkers for
early myocardial damage and coronary atheroscle-
rotic plaque as determined by cardiac CTA is com-
plementary in the management of patients with acute
chest pain. Although both approaches leave a large
portion of patients in an intermediate risk category
that requires further admission and testing, syner-
gistic workﬂows can signiﬁcantly improve the man-
agement of these subjects. The present study forms
an intriguing basis to justify a large-scale randomized
trial to prove that “the whole is greater than the sum
of its parts.”
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